Agilent Technologies completed the acquisition of BIOVECTRA for $925m.

Agilent Technologies, an analytical and clinical laboratory technologies firm, completed the acquisition of BIOVECTRA, a global biotech and pharmaceutical company, for $925m. “We are delighted to officially welcome the BIOVECTRA team to Agilent. This acquisition demonstrates our commitment to providing customers the most advanced capabilities to accelerate their therapeutics programs, including best-in-class cGMP pharmaceutical manufacturing,” Padraig McDonnell, Agilent President and CEO.